Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population.

Ludwig, H; Ponisch, W; Knop, S; Egle, A; Hinke, A; Schreder, M; Lechner, D; Hajek, R; Gunsilius, E; Petzer, A; Weisel, K; Niederwieser, D; Einsele, H; Willenbacher, W; Rumpold, H; Pour, L; Jelinek, T; Krenosz, KJ; Meckl, A; Nolte, S; Melchardt, T; Greil, R; Zojer, N Leuk Lymphoma. 2020; 61(2):377-386

Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer.

Brandberg, Y; Johansson, H; Hellström, M; Gnant, M; Möbus, V; Greil, R; Foukakis, T; Bergh, J; Breast Cancer Res Treat. 2020; 181(1):87-96

External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients.

Barth, DA; Brenner, C; Riedl, JM; Prinz, F; Klocker, EV; Schlick, K; Kornprat, P; Lackner, K; St?ger, H; Stotz, M; Gerger, A; Pichler, M CANCER MED-US. 2020; 9(15): 5473-5479.

Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomised, neoadjuvant phase II study (ABCSG 34).

Singer, CF; Pfeiler, G; Hubalek, M; Bartsch, R; Stoger, H; Pichler, A; Petru, E; Bjelic-Radisic, V; Greil, R; Rudas, M; Tea, MKM; Wette, V; Petzer, AL; Sevelda, P; Egle, D; Dubsky, PC; Filipits, M; Fitzal, F; Exner, R; Jakesz, R; Balic, M; Tinchon, C; Bago-Horvath, Z; Frantal, S; Gnant, M EUR J CANCER. 2020; 132: 43-52.

Therapies in flux: highlights of the 2019 San Antonio Breast Cancer Symposium (SABCS)

Gampenrieder, SP MEMO-MAG EUR MED ONC. 2020; 13(3): 253-254.

A cross-trial comparison of single-agent ibrutinib

Tedeschi, A; Greil, R; Demirkan, F; Robak, T; Moreno, C; Barr, PM; Anz, B; Simpson, D; Gaidano, G; Bairey, O; Stevens, D; Gill, D; Flinn, IW; Kipps, TJ; Burger, JA; Lin, J; Webb, T; Fedorov, V; Styles, L; Gribben, JG; Haematologica. 2020; 105(4):e164-e168

Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial.

Rinnerthaler, G; Gampenrieder, SP; Hackl, H; Steiner, M; Monzo-Fuentes, C; Melchardt, T; Magnes, T; Huemer, F; Westphal, T; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Greil, R; J Clin Med. 2020; 9(6):

Correction to: The relative risk of second primary cancers in Switzerland: a population-based retrospective cohort study.

Bjelic-Radisic, V; Fitzal, F; Knauer, M; Steger, G; Egle, D; Greil, R; Schrenk, P; Balic, M; Singer, C; Exner, R; Soelkner, L; Gnant, M BMC CANCER. 2020; 20(1): 87

A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting : R-EFECT study.

Petzer, AL; Sperr, WR; Buxhofer-Ausch, V; Sliwa, T; Schmidt, S; Greil, R; Wölfler, A; Pichler, P; Dormann, C; Burgstaller, S; Tinchon, C; Lang, A; Goebel, F; Uthman, S; Muenchmeier, N; Valent, P; Wien Klin Wochenschr. 2020; 132(15-16):415-422

Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.

Steger, GG; Egle, D; Bartsch, R; Pfeiler, G; Petru, E; Greil, R; Helfgott, R; Marth, C; Öhler, L; Hubalek, M; Lang, A; Tinchon, C; Haslbauer, F; Redl, A; Hock, K; Hennebelle, M; Mraz, B; Gnant, M; Breast. 2020; 50:64-70